Clinical TrialAug 10, 2026, 07:06 AM
Sionna's SION-719 Phase 2a trial fails key endpoint; program halted
AI Summary
Sionna Therapeutics reported that its SION-719 Phase 2a proof-of-concept trial did not meet its key activity endpoint of sweat chloride reduction when added to standard of care. Consequently, the company will not advance SION-719 as an add-on therapy. Sionna is evaluating potential confounders from the SION-719 trial to inform next steps for its SION-451 dual combination clinical program, which showed positive Phase 1 safety and pharmacokinetic results. The company ended Q2 with approximately $268.3 million in cash and plans to preserve capital.
Key Highlights
- SION-719 Phase 2a trial did not achieve key activity endpoint of sweat chloride reduction.
- Mean placebo-adjusted sweat chloride change was -1.0 mmol/L (p=0.7).
- Sionna will not advance SION-719 as an add-on to standard of care.
- SION-451 + SION-2222 identified as preferred dual combination from Phase 1 trial.
- Ended Q2 with approximately $268.3 million in cash, cash equivalents, and marketable securities.
- Company plans to take actions to preserve capital while evaluating next steps.
Price Impact
More from SION